Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Novel Mutational Signatures Associated with Isoniazid Resistance in Mycobacterium tuberculosis

PROVIDER: PRJEB3390 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR202386.fastq.gz	Fastqsanger.gz
	ERR202387.fastq.gz	Fastqsanger.gz
	ERR202388.fastq.gz	Fastqsanger.gz
	ERR202389.fastq.gz	Fastqsanger.gz
	ERR202390.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 40

Similar Datasets

Effect of addition of cysteine to isoniazid treatment of Mycobacterium tuberculosis

Project description:Transcriptional profiling of Mycobacterium tuberculosis H37Rv after 4 hours of combination isoniazid and cysteine treatment relative to treatment with isoniazid alone.

2017-03-27 | GSE86184 | GEO

Mycobacterium tuberculosis Persister Stimulon

Project description:Transcriptional profiling of Mycobacterium tuberculosis mc2 7000 surviving 4 days of isoniazid treatment relative to untreated to investigate genes relevant to survival in genotypically isoniazid-sensitive cells

2016-09-23 | GSE86141 | GEO

PatA mediates biofilm formation and drugs resistance through regulating the synthesis of glycolipids and lipids in mycobacterium PatA mediates a novel mycolic acid synthesis pathway and regulates biofilm formation in mycobacterium

Project description:Glycolipids and lipids are prominent components of bacterial cell wall that play critical roles not only in maintaining the biofilm formation but also in resistance to environmental stress. PatA is an essential membrane associated acyltransferase involved in the biosynthesis of phosphatidyl-myo-inositol mannosides (PIMs), which are the key glycolipid components in the cell wall of Mycobacterium tuberculosis. However, whether or not PatA regulates the lipids synthesis and affects drugs resistance and biofilm formation in mycobacterium is unclear, and the mechanisms involved remain to be explored. Here we show that PatA can directly regulate the synthesis of glycolipids and lipids to maintain the drugs resistance and biofilm formation in Mycobacterium smegmatis. Interestingly, the INH resistance of patA-deleted mutant is significantly enhanced although its biofilm formation is reduced. This is due to PatA negative regulation the synthesis of mycolic acids through a novel mycolic acid synthesis pathway other than the FAS pathway, which could efficiently counteract the inhibition of isoniazid on mycolic acids synthesis in mycobacterium. Furthermore, PatA is highly conserved including amino acid sequences and physiological functions in mycobacterium. Therefore, PatA regulates the synthesis of glycolipids and lipids to affect drugs resistance and biofilm formation in mycobacterium. Our findings provide a novel mycolic acids synthetic pathway and novel insights into the molecular mechanism of glycolipids and lipids metabolism regulation and their correlation with bacterial physiological phenotypes.

2023-05-22 | MTBLS6758 | MetaboLights

Small RNAs in anti-tuberculosis drug-induced liver injury

Project description:The antimicrobials isoniazid and pyrazinamide, used for the treatment of tuberculosis are known to cause drug-induced liver injury in humans. This limits the effectiveness of tuberculosis treatment, resulting in incomplete cure, relapse and the development of antimicrobial resistance. MicroRNAs are known to be good biomarkers of disease, with the microRNA miR-122 being diagnostic for liver injury. In this study zebrafish larvae were exposed to the anti-tuberculosis drugs isoniazid and pyrazinamide at concentrations which demonstrated liver injury by microscopy and histology. The aim of this study is to understand small RNA changes occurring in anti-tuberculosis drug-induced liver injury and to attempt to identify novel microRNA biomarkers of liver injury.

2023-12-25 | GSE146260 | GEO

Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis

Project description:Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis

| PRJNA532912 | ENA

Accumulation of inorganic polyphosphate mediates metabolic downshift and antibiotic tolerance in Mycobacterium tuberculosis

Project description:The stringent response, involving the regulatory molecules inorganic polyphosphate (poly P) and (p)ppGpp, is believed to mediate Mycobacterium tuberculosis persistence. In this study, we identified a novel exopolyphosphatase responsible for poly P hydrolysis. Using two different poly P-accumulating M. tuberculosis recombinant strains, we found that increased poly P content drives the organisms into early growth arrest, and contributes to tolerance to the cell wall-active agent isoniazid, increased resistance to stress conditions, and improved survival in macrophages. Transcriptomic and metabolomics analysis revealed metabolic downshift manifested by reduced expression of the transcriptional and translational machinery, and shift from utilization of glucose as a carbon source. In summary, regulation of the poly P balance is critical for persister formation in M. tuberculosis.

2015-02-20 | GSE57868 | GEO

Effects of manganese and its concomitant administration with isoniazid on macrophages infected with Mycobacterium tuberculosis

Project description:In order to study the effect of manganese on the immunity of macrophages, we established a model of infection with Mycobacterium tuberculosis and treated it with manganese and isoniazid for 12 hours

2022-08-26 | GSE211666 | GEO

Accumulation of inorganic polyphosphate mediates metabolic downshift and antibiotic tolerance in Mycobacterium tuberculosis

2015-02-20 | E-GEOD-57868 | biostudies-arrayexpress

Lefamulin: A Novel Pleuromutilin Effective Against Mycobacterium tuberculosis via Efflux Inhibition

Project description:Tuberculosis (TB) remains a major global health challenge, exacerbated by the increasing prevalence of drug-resistant strains. Drug repurposing is a crucial strategy for TB control, particularly in combating resistance. Through this approach, the anti-TB potential of lefamulin was identified as a candidate for systemic administration. Lefamulin demonstrates potent inhibitory activity against Mycobacterium tuberculosis (M.tb) in vitro , in vivo, and within intracellular environments. Notably, it exhibits synergistic effects when combined with the first-line anti-TB drugs rifampicin and isoniazid, as demonstrated in insect model.

2025-06-04 | GSE280850 | GEO

Exploring proteomic change of intracellular Mycobacterium tuberculosis in response to the Apt-PEGNio/EEP

Project description:The challenge in treating tuberculosis (TB) associated with drug resistance and toxicity drives the efforts in the development of alternative strategies to combat Mycobacterium tuberculosis (Mtb), a major causative pathogen in humans. Propolis extract is considered a promising therapeutic agent since the findings on its effective functions against Mtb.

2025-11-26 | PXD058274 | JPOST Repository

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data